Program
Tirzepatide
Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.
Drug pageTirzepatide: every studyAll 192 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 6917 open or running | phase 4since Jun 22, 2022 | Apr 29, 2016 | Nov 2026phase 1 · NCT07299084 |
| Florida Academic Centers Research and Educationits history only | 11 open or running | no phasesince Mar 1, 2024 | Mar 1, 2024 | none ahead |
| Hudson Biotechits history only | 11 open or running | phase 3since Mar 8, 2026 | Mar 8, 2026 | Feb 14, 2027phase 3 · NCT07481747 |
| Lexaria Bioscienceits history only | 10 open or running | phase 1since Oct 16, 2024 | Oct 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 43 earlier studies, May 15, 2019 to Sep 4, 2024.
- Jun 9, 2018Named tirzepatideINNProposed as its International Nonproprietary Name in WHO's List 119
- Oct 4, 2024Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06635057 · 166 enrolled · Saudi Arabia, United Arab Emirates
- Oct 14, 2024Phase 2 study in ObesityEli Lilly · NCT06643728 · 252 enrolled · United States
- Oct 16, 2024Lexaria Bioscience’s first study: phase 1 study in Type2diabetesNew to Lexaria BioscienceLexaria Bioscience · NCT06648031 · 148 enrolled · Australia
- Mar 3, 20252 phase 4 studiesEli Lilly · NCT06864026, NCT06857942
- Mar 24, 2025Phase 2 study in ObesityEli Lilly · NCT06901349 · United States, Argentina, Canada and more
- Apr 4, 20253 phase 3 studiesEli Lilly · NCT06914895, NCT06937099, NCT06937086
- May 6, 2025Phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280 · 465 enrolled · United States, Argentina, Brazil and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 19, 2025Phase 4 study in ObesityEli Lilly · NCT07247084 · 3,000 planned · United Kingdom
- Dec 10, 2025Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084 · 40 enrolled · Singapore
- Feb 23, 2026Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07438444 · 344 enrolled · India
- Mar 8, 2026Hudson Biotech’s first study: phase 3 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07481747 · 2,539 planned · China
- Sep 1, 2026Phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744 · 18 planned · United States
- Sep 9, 2026Phase 3 study in ObesityEli Lilly · NCT07817875 · 150 planned · United States, Belgium, Israel and more
Ahead
- Nov 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06914895
- Dec 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744
TargetBeta
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07817875Obesity · United States, Belgium, Israel and more | 3 | Recruiting | Eli Lilly | Dec 2029 | 150 |
| NCT07803744Diabetes Mellitus, Type 1 · United States | 1 | Recruiting | Eli Lilly | Dec 2026 | 18 |
| NCT07481747Obesity · China | 3 | Recruiting | Hudson Biotech | Feb 14, 2027 | 2,539 |
| NCT07438444Diabetes Mellitus, Type 2 · India | 4 | Active, not recruiting | Eli Lilly | Jul 2027 | 344 |
| NCT07299084Diabetes Mellitus, Type 2 · Singapore | 1 | Active, not recruiting | Eli Lilly | Nov 2026 | 40 |
| NCT07247084Obesity · United Kingdom | 4 | Recruiting | Eli Lilly | Jul 2029 | 3,000 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Aug 2030 | 4,500 |
| NCT06962280Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 465 |
| NCT06937099Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | May 2028 | 290 |
| NCT06937086Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Apr 2028 | 350 |
| NCT06914895Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 905 |
| NCT06901349Obesity · United States, Argentina, Canada and more | 2 | Withdrawn | Eli Lilly | Jun 10, 2025 | 0 |
| NCT06864026Arthritis, Psoriatic · United States, Puerto Rico | 4 | Active, not recruiting | Eli Lilly | Aug 2027 | 200 |
| NCT06857942Psoriasis · United States | 4 | Recruiting | Eli Lilly | May 2028 | 200 |
| NCT06648031Type2diabetes · Australia | 1 | Completed | Lexaria Bioscience | Jul 31, 2025 | 148 |
| NCT06643728Obesity · United States | 2 | Completed | Eli Lilly | Jan 16, 2026 | 252 |
| NCT06635057Diabetes Mellitus, Type 2 · Saudi Arabia, United Arab Emirates | 4 | Completed | Eli Lilly | Apr 15, 2026 | 166 |
| NCT06588296Arthritis, Psoriatic · United States, Puerto Rico | 3 | Completed | Eli Lilly | Nov 18, 2025 | 279 |
| NCT06588283Psoriasis · United States, Puerto Rico | 3 | Completed | Eli Lilly | Jan 8, 2026 | 281 |
| NCT06439277Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Oct 2027 | 300 |
| NCT06301256Hidradenitis Suppurativa | – | Not yet recruiting | Florida Academic Centers Research and Education | Mar 11, 2025 | 20 |
| NCT06075667Obesity · United States, Canada, Czechia and more | 3 | Active, not recruiting | Eli Lilly | Jun 2, 2026 | 160 |
| NCT06047548Overweight · United States | 3 | Completed | Eli Lilly | Jan 20, 2026 | 441 |
| NCT06037252Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more | 2 | Active, not recruiting | Eli Lilly | Jan 8, 2026 | 414 |
| NCT05978713Healthy · United States | 1 | Completed | Eli Lilly | Mar 12, 2024 | 11 |
| NCT05963022Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Oct 9, 2024 | 206 |
| NCT05810597Healthy · United States | 1 | Completed | Eli Lilly | Jul 17, 2023 | 65 |
| NCT05706506Diabetes Mellitus, Type 2 · United States | 4 | Completed | Eli Lilly | Oct 31, 2023 | 152 |
| NCT05696847Obesity · United States | 1 | Completed | Eli Lilly | Jan 16, 2025 | 28 |
| NCT05691712Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Jul 1, 2024 | 257 |
| NCT05564039Diabetes Mellitus, Type 2 · United States, Belgium, Germany and more | 4 | Completed | Eli Lilly | Jul 15, 2024 | 282 |
| NCT05556512Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Oct 2027 | 15,374 |
| NCT05822830Obesity · United States, Puerto Rico | 3 | Completed | Eli Lilly | Nov 13, 2024 | 751 |
| NCT05536804Overweight · United States, Austria, Canada and more | 2 | Completed | Eli Lilly | Jul 6, 2026 | 134 |
| NCT05433584Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 4 | Active, not recruiting | Eli Lilly | Oct 21, 2025 | 794 |
| NCT05412004Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Mar 12, 2024 | 469 |
| NCT05260021Diabetes Mellitus · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Jul 30, 2024 | 99 |
| NCT05024032Obesity · China | 3 | Completed | Eli Lilly | Dec 27, 2022 | 210 |
| NCT04844918Obesity · Japan | 3 | Completed | Eli Lilly | Jun 24, 2023 | 267 |
| NCT04847557Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Jul 2, 2024 | 731 |
| NCT04660643Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 25, 2023 | 783 |
| NCT04657016Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 20, 2023 | 579 |
| NCT04657003Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Mar 16, 2023 | 938 |
| NCT04537923Diabetes Mellitus, Type 2 · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Oct 11, 2022 | 1,428 |
| NCT04407234Overweight · United States | 1 | Completed | Eli Lilly | Jan 7, 2021 | 36 |
| NCT04311424Healthy · United Kingdom | 1 | Completed | Eli Lilly | Oct 2, 2020 | 6 |
| NCT04311411Obesity · United States | 1 | Completed | Eli Lilly | Dec 16, 2022 | 114 |
| NCT04255433Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 12, 2025 | 13,299 |
| NCT04235959Diabetes Mellitus, Type 2 · China | 1 | Completed | Eli Lilly | Aug 17, 2021 | 24 |
| NCT04184622Overweight · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 1, 2022 | 2,539 |
| NCT04172987Healthy · United States | 1 | Completed | Eli Lilly | Feb 9, 2021 | 40 |
| NCT04166773Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Eli Lilly | Dec 11, 2023 | 190 |
| NCT04093752Diabetes Mellitus, Type 2 · Australia, China, India and more | 3 | Completed | Eli Lilly | Nov 1, 2021 | 917 |
| NCT04081337Obesity · United States | 1 | Completed | Eli Lilly | May 26, 2022 | 55 |
| NCT04050670Healthy · United States | 1 | Completed | Eli Lilly | Apr 3, 2020 | 54 |
| NCT04050553Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Eli Lilly | Jan 25, 2022 | 42 |
| NCT04039503Diabetes Mellitus, Type 2 · United States, Czechia, Germany and more | 3 | Completed | Eli Lilly | Dec 22, 2020 | 475 |
| NCT04004988Healthy · Singapore | 1 | Completed | Eli Lilly | Dec 16, 2019 | 47 |
| NCT03987919Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 28, 2021 | 1,879 |
| NCT03954834Diabetes Mellitus, Type 2 · United States, India, Japan and more | 3 | Completed | Eli Lilly | Oct 5, 2020 | 478 |
How it is read
Names in the registry
- “Tirzepatide”, 69 entries
- “Arm 5- Tirzepatide”, 1 entry
- “Tirzepatide Dose 1”, 1 entry
- “Tirzepatide Dose 2”, 1 entry
- “TIRZEPATIDE”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 29 studies
- Obesity, 21 studies
- Diabetes Mellitus, Type 1, 3 studies
- Psoriasis, 2 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.